Recent Advances in α-Synuclein Functions, Advanced Glycation, and Toxicity: Implications for Parkinson’s Disease
Abstract
The toxicity of α-synuclein in the neuropathology of Parkinson's disease which includes its hallmark aggregation has been studied scrupulously in the last decade. Although little is known regarding the normal functions of α-synuclein, its association with membrane phospholipids suggests its potential role in signaling pathways. Following extensive evidences for its nuclear localization, we and others recently demonstrated DNA binding activity of α-synuclein that modulates its conformation as well as aggregation properties. Furthermore, we also underscored the similarities among various amyloidogenic proteins involved in neurodegenerative diseases including amyloid beta peptides and tau. Our more recent studies show that α-synuclein is glycated and glycosylated both in vitro and in neurons, significantly affecting its folding, oligomeric, and DNA binding properties. Glycated α-synuclein causes increased genome damage both via its direct interaction with DNA and by increased generation of reactive oxygen species as glycation byproduct. In this review, we discuss the mechanisms of glycation and other posttranslational modifications of α-synuclein, including phosphorylation and nitration, and their role in neuronal death in Parkinson's disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
RAGE receptor was highly expressed in PD patients.
“RAGEs receptor was also highly expressed in PD patients,338”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [338]
In PD brains, AGEs accumulate early in newly formed Lewy bodies.
“In PD brains, AGEs can accumulate early in newly formed Lewy bodies, suggesting that AGEs could play a contributing role in Lewy body formation in developing PD115.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [115]
AGEs play a contributing role in Lewy body formation in developing PD.
“In PD brains, AGEs can accumulate early in newly formed Lewy bodies, suggesting that AGEs could play a contributing role in Lewy body formation in developing PD115.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [115]
AGEs cross-linked with α-synuclein are present in PD brains and result in aggregation of α-synuclein toxic oligomers.
“AGEs cross-linked with α-synuclein are also present in PD brains, resulting in the aggregation of α-synuclein toxic oligomers115,116.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [115]
The citation lists haven’t been fetched yet
References 91 · Cited by 121
- Authors
- Guerrero, E., Vasudevaraju, P., Hegde, M. L., Britton, G. B., & Rao, K. S.
- Affiliations
- Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (PA)
- Medical University of South Carolina (US)
- The University of Texas Medical Branch at Galveston (US)
- Corresponding author
- Rao, K. S.
- Venue
- Molecular Neurobiology
- Published
- 2012-08-26
- Volume
- 47
- Issue
- 2
- Pages
- 525-536
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2088529103
- Cited by
- 121
- References
- 91
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 4 · 2023: 15 · 2022: 7 · 2021: 13 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 6 · 2016: 9 · 2015: 10 · 2014: 6 · 2013: 4 · 2012: 2
- FWCI
- 0.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- alpha-synuclein, Parkinson's disease, advanced glycation, glycosylation, protein aggregation, DNA binding, post-translational modification, phosphorylation, nitration, reactive oxygen species, neuronal cell death, amyloidogenic proteins, tau protein, amyloid-beta, neurodegeneration, membrane phospholipids
- MeSH terms
- Animals, Glycosylation, Humans, Parkinson Disease, Phosphorylation, Protein Binding, Cell Death, Glycation End Products, Advanced, Protein Folding, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review